Document 2987
 DOCN  M94A2987
 TI    Daunoxome-phase II trial for epidemic Kaposi's sarcoma (EKS).
 DT    9412
 AU    Wernz JC; Taubes B; Friedberg A; NYU Kaplan Cancer Center, NY.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):18 (abstract no. 046B). Unique
       Identifier : AIDSLINE ICA10/94369588
 AB    In January 1993 accrual began at NYU Medical Center using the
       investigational drug Daunoxome for previously treated patients with
       progressive EKS. As of February 18, 1994 42 patients had been entered on
       study. Daunoxome is a combination of daunorubicin and a phospholipid
       vesicle carrier (liposome) specifically developed for its tumor
       targeting abilities. The drug appears to be most active in reducing the
       EKS associated edema which frequently is a major problem in advanced
       EKS. The drug is given in the outpatient setting every two weeks at a
       dose of 40mg/m2. If there is no response after two cycles, the dose is
       increased to 60mg/m2. Response was graded according to the ACTG response
       criteria. 14/42 patients achieved a partial response (PR) and 28/42
       remained with stable disease (SD). 10/14 patients continue with PR. The
       median duration of response at 40mg/m2 is 9+ weeks (2-44+) and at
       60mg/m2 is 7.5+ weeks (4-52+). 20 patients remain on study. Neutropenia
       is a dose limiting toxicity; however, patients can be kept on schedule
       with Neupogen support. There is essentially no alopecia and minimal
       nausea. To this date there has been no evidence of cardiac toxicity.
       Daunoxome is effective in advanced EKS in patients who have progressed
       on previous chemotherapy and has a very high patient acceptance.
 DE    Daunorubicin/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS  Drug Carriers
       Granulocyte Colony-Stimulating Factor/THERAPEUTIC USE  Human
       Lymphedema/DRUG THERAPY/ETIOLOGY  Neutropenia/CHEMICALLY INDUCED
       Recombinant Proteins/THERAPEUTIC USE  Sarcoma,
       Kaposi's/COMPLICATIONS/*DRUG THERAPY  CLINICAL TRIAL  CLINICAL TRIAL,
       PHASE II  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).